title: [Evaluation of the immunogenic and reactogenic properties of vaccine "Euvax B" in persons aged 16-18 years in different geographical zones of Russia].
abstract: The comparative evaluation of the reactogenic and immunogenic properties of vaccine "Euvax B" in adolescents aged 16-18 years was carried out in factory housing estate Lvovsky, the Podolsk district, the Moscow region, and in the Yamalo-Nenets Autonomous District (AD): in towns Salekhard, Noyabrsk, Muravlenko, in housing estate Tarko-Sale. The evaluation demonstrated that the use of this vaccine in a dose of 20 mg/ml produced no postvaccinal complications and the frequency of postvaccinal reactions was insignificant. Postvaccinal anti-HBs were detected, on the average, in protective concentrations in 98.4 +/- 1.8% of the vaccines (99.0 +/- 1.9% in the Moscow region, 97.7 +/- 3.2% in the Yamalo-Nenets AD). In most of the vaccinated adolescents high concentrations of postvacinal anti-HBs were detected: in 51.4 +/- 9.7% of the vaccinees in the Moscow region and in 89.7 +/- 6.4% in the Yamalo-Nenets AD they exceeded 1,000 I.U./lit. The conclusion was made that in the territories located in subarctic latitudes vaccinal prophylaxis against hepatitis B was safe and highly effective and have no limitations connected with the conditions of the Far North.
authors.forename: S N
authors.initials: SN
authors.lastname: Kuzin
authors.forename: A L
authors.initials: AL
authors.lastname: Zaplatnikov
authors.forename: F A
authors.initials: FA
authors.lastname: Ibragimova
authors.forename: N N
authors.initials: NN
authors.lastname: Skvortsova
authors.forename: L A
authors.initials: LA
authors.lastname: Nechepurenko
authors.forename: B M
authors.initials: BM
authors.lastname: Raengulov
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Volova
authors.forename: T M
authors.initials: TM
authors.lastname: Popov
authors.forename: I V
authors.initials: IV
authors.lastname: Makarenko
authors.forename: T F
authors.initials: TF
authors.lastname: Karpova
authors.forename: V V
authors.initials: VV
authors.lastname: Reshetniak
authors.forename: G G
authors.initials: GG
authors.lastname: Kerivtsova
authors.forename: I A
authors.initials: IA
authors.lastname: Varlamova
authors.forename: L E
authors.initials: LE
authors.lastname: Kuzina
authors.forename: N A
authors.initials: NA
authors.lastname: Malyshev
authors.forename: V V
authors.initials: VV
authors.lastname: Zverev
mesh_terms: D000293:Adolescent; D004334:Drug Administration Schedule; D005260:Female; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006801:Humans; D008297:Male; D012426:Russia; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014761:Viral Hepatitis Vaccines